AstraZeneca has restarted the U.

S trial of its experimental Cove in 19 vaccine, and Johnson and Johnson is set to resume its trial on Monday or Tuesday.

AstraZeneca said Friday the U.

S Food and Drug Administration has deemed it safe to continue testing the vaccine.

The company had deposits US trial last month after a report of a serious neurological illness in a participant in its trial in the UK it is developing its vaccine with researchers at Oxford University.

Johnson and Johnson said Friday that the independent safety panel, the Data and Safety Monitoring Board, has recommended that it resumed trial recruitment after finding no evidence that the vaccine caused a volunteer to fall ill.

The company says it's on track to produce trial data of the vaccine's effectiveness by the end of this year or early 2021.

Both companies have contracts to supply vaccines to the US and other governments if they're cleared by regulators.